Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

733 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: A Subgroup Analysis of Asian Patients in the Phase 3 KEYNOTE-240 Trial.
Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY. Kudo M, et al. Among authors: morimoto n. Liver Cancer. 2021 Jun;10(3):275-284. doi: 10.1159/000515553. Epub 2021 Apr 27. Liver Cancer. 2021. PMID: 34239813 Free PMC article.
Safety and tolerance of sorafenib in Japanese patients with advanced hepatocellular carcinoma.
Ogasawara S, Kanai F, Obi S, Sato S, Yamaguchi T, Azemoto R, Mizumoto H, Koushima Y, Morimoto N, Hirata N, Toriyabe T, Shinozaki Y, Ooka Y, Mikata R, Chiba T, Okabe S, Imazeki F, Yoshikawa M, Yokosuka O. Ogasawara S, et al. Among authors: morimoto n. Hepatol Int. 2011 Sep;5(3):850-6. doi: 10.1007/s12072-010-9249-4. Epub 2011 Jan 22. Hepatol Int. 2011. PMID: 21484134
Hepatitis C virus eradication prolongs overall survival in hepatocellular carcinoma patients receiving molecular-targeted agents.
Seko Y, Moriguchi M, Takahashi A, Yamaguchi K, Umemura A, Okuda K, Kataoka S, Unozawa H, Kobayashi K, Ogasawara S, Sato R, Tsuchiya S, Watanabe S, Morimoto N, Iwai K, Aramaki T, Kato N, Itoh Y. Seko Y, et al. Among authors: morimoto n. J Gastroenterol. 2022 Feb;57(2):90-98. doi: 10.1007/s00535-021-01837-5. Epub 2022 Jan 15. J Gastroenterol. 2022. PMID: 35031857
Evolution of Survival Impact of Molecular Target Agents in Patients with Advanced Hepatocellular Carcinoma.
Kobayashi K, Ogasawara S, Takahashi A, Seko Y, Unozawa H, Sato R, Watanabe S, Moriguchi M, Morimoto N, Tsuchiya S, Iwai K, Inoue M, Ogawa K, Ishino T, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Koroki K, Nakamura M, Kanogawa N, Kiyono S, Kondo T, Saito T, Nakagawa R, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Nagashima K, Kato J, Isoda N, Aramaki T, Itoh Y, Kato N. Kobayashi K, et al. Among authors: morimoto n. Liver Cancer. 2021 Dec 6;11(1):48-60. doi: 10.1159/000519868. eCollection 2022 Jan. Liver Cancer. 2021. PMID: 35222507 Free PMC article.
A Prospective Study Exploring the Safety and Efficacy of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma and High Tumor Burden: The LAUNCH Study.
Kobayashi K, Ogasawara S, Maruta S, Okubo T, Itokawa N, Haga Y, Seko Y, Moriguchi M, Watanabe S, Shiko Y, Takatsuka H, Kanzaki H, Koroki K, Inoue M, Nakamura M, Kiyono S, Kanogawa N, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Inaba Y, Ikeda M, Okabe S, Morimoto N, Itoh Y, Nakamura K, Ito K, Azemoto R, Atsukawa M, Itobayashi E, Kato N. Kobayashi K, et al. Among authors: morimoto n. Clin Cancer Res. 2023 Dec 1;29(23):4760-4769. doi: 10.1158/1078-0432.CCR-23-1462. Clin Cancer Res. 2023. PMID: 37796614
Conventional Therapies Do Not Prolong the Prognosis of Hepatocellular Carcinoma Patients with Extrahepatic Metastases under Receiving of Tyrosine Kinase Inhibitors.
Maeda H, Miura K, Morimoto N, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Goka R, Sato N, Morishima K, Sakuma Y, Sata N, Fukushima N, Isoda N, Yamamoto H. Maeda H, et al. Among authors: morimoto n. Cancers (Basel). 2022 Jan 31;14(3):752. doi: 10.3390/cancers14030752. Cancers (Basel). 2022. PMID: 35159018 Free PMC article.
Usefulness of Gd-EOB-DTPA-enhanced MRI for evaluating the potential for early development of hepatocellular carcinoma after HCV eradication by direct-acting antiviral treatment.
Morimoto N, Miura K, Watanabe S, Tsukui M, Takaoka Y, Nomoto H, Murayama K, Hirosawa T, Goka R, Kunitomo N, Nakamura H, Sugimoto H, Isoda N, Yamamoto H. Morimoto N, et al. J Rural Med. 2019 May;14(1):78-86. doi: 10.2185/jrm.2993. Epub 2019 May 30. J Rural Med. 2019. PMID: 31191770 Free PMC article.
733 results